Esra Terzi Demirsoy
Overview
Explore the profile of Esra Terzi Demirsoy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
44
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Acar I, Aslaner Ak M, Akyol G, Kars T, Ipek Y, Uysal A, et al.
Medicina (Kaunas)
. 2024 Oct;
60(10).
PMID: 39459410
Acute myeloid leukemia and myelodysplastic syndrome are both clonal hematologic malignancies that primarily affect older adults. Current treatments for AML/MDS are both limited in number and efficacy. This study aims...
2.
Geduk A, Polat M, Terzi Demirsoy E, Oztas B, Eryilmaz B, Yenihayat E, et al.
Turk J Haematol
. 2024 Mar;
41(2):83-90.
PMID: 38426298
Objective: Calprotectin (CLP), S100A6, and high mobility group nucleosome-binding protein 1 (HMGN1), known as alarmins, are involved in the pathogenesis of many tumors. In this study, we aimed to investigate...
3.
Tekinalp A, Geduk A, Akdeniz A, Terzi Demirsoy E, Gursoy V, Aslaner Ak M, et al.
Turk J Haematol
. 2023 Nov;
40(4):242-250.
PMID: 37961952
Objective: This study aimed to evaluate patients with relapsed/refractory multiple myeloma (RRMM) who underwent daratumumab (DARA) therapy. Materials And Methods: This multicenter retrospective study included 134 patients who underwent at...
4.
Geduk A, Oztas B, Eryilmaz B, Terzi Demirsoy E, Menguc M, Unal S, et al.
Indian J Hematol Blood Transfus
. 2023 Jun;
39(3):518.
PMID: 37304480
[This corrects the article DOI: 10.1007/s12288-022-01574-6.].
5.
Geduk A, Oztas B, Eryilmaz B, Terzi Demirsoy E, Menguc M, Unal S, et al.
Indian J Hematol Blood Transfus
. 2023 Apr;
39(2):220-227.
PMID: 37006982
Purpose: The receptor for advanced glycation end products (RAGE) upregulated during the onset and progression of cancer and bone-related pathologies. In this study, we aimed to investigate the role of...
6.
Terzi Demirsoy E, Mehtap O, Birtas Atesoglu E, Tarkun P, Geduk A, Eren N, et al.
Indian J Hematol Blood Transfus
. 2022 Jun;
38(3):454-463.
PMID: 35747582
Multiple myeloma is the plasma cell malignancy in which bone involvement is common. The Fibroblast growth factor-23 (FGF-23)/Klotho pathway plays a major role in mineral metabolism that FGF-23 is mineralization...
7.
Albayrak C, Tarkun P, Birtas Atesoglu E, Eraldemir C, Ozsoy O, Terzi Demirsoy E, et al.
Turk J Med Sci
. 2019 Feb;
49(1):74-80.
PMID: 30761871
Background/aim: GDF15, hepcidin and mitoferrin-1 (mfrn-1) are proteins involved in systemic iron regulation. There are no studies in the literature demonstrating the serum mfrn-1 levels in polycythemia vera (PV) and...
8.
Terzi Demirsoy E, Birtas Atesoglu E, Eren N, Geduk A, Mehtap O, Tarkun P, et al.
Tumori
. 2018 Dec;
105(6):NP24-NP27.
PMID: 30580656
Background: Tumor lysis syndrome (TLS) is a potentially fatal complication of cancer therapy characterized by severe electrolyte and metabolic abnormalities such as hyperphosphatemia, hyperkalemia, and hypocalcaemia. TLS usually occurs in...
9.
Terzi Demirsoy E, Mehtap O, Birtas Atesoglu E, Tarkun P, Eren N, Geduk A, et al.
Transfus Apher Sci
. 2018 Feb;
57(2):222-224.
PMID: 29475747
Most commonly seen side effects with Tyrosine kinase inhibitors (TKI's) are hematologic toxicities. Besides, with dasatinib autoimmune side effects can be seen. Thrombotic thrombocytopenic purpura (TTP) is a life- threatening...
10.
Terzi Demirsoy E, Birtas Atesoglu E, Tarkun P, Geduk A, Erdem B, Hacihanefioglu A, et al.
Indian J Hematol Blood Transfus
. 2016 Jul;
32(Suppl 1):201-4.
PMID: 27408391
Isolated breast relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is less often seen. Chronic graft-versus-host disease (cGVHD) is effective in preventing marrow relapse, but cGVHD seems not to be...